BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 30472020)

  • 1. KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.
    Hinohara K; Wu HJ; Vigneau S; McDonald TO; Igarashi KJ; Yamamoto KN; Madsen T; Fassl A; Egri SB; Papanastasiou M; Ding L; Peluffo G; Cohen O; Kales SC; Lal-Nag M; Rai G; Maloney DJ; Jadhav A; Simeonov A; Wagle N; Brown M; Meissner A; Sicinski P; Jaffe JD; Jeselsohn R; Gimelbrant AA; Michor F; Polyak K
    Cancer Cell; 2018 Dec; 34(6):939-953.e9. PubMed ID: 30472020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
    Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
    J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM5 lysine demethylases are involved in maintenance of 3'UTR length.
    Blair LP; Liu Z; Labitigan RL; Wu L; Zheng D; Xia Z; Pearson EL; Nazeer FI; Cao J; Lang SM; Rines RJ; Mackintosh SG; Moore CL; Li W; Tian B; Tackett AJ; Yan Q
    Sci Adv; 2016 Nov; 2(11):e1501662. PubMed ID: 28138513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
    Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
    Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance.
    Gaillard S; Charasson V; Ribeyre C; Salifou K; Pillaire MJ; Hoffmann JS; Constantinou A; Trouche D; Vandromme M
    Biol Open; 2021 May; 10(5):. PubMed ID: 34184733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design and discovery of potent and selective KDM5 inhibitors.
    Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
    Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
    Shokri G; Doudi S; Fathi-Roudsari M; Kouhkan F; Sanati MH
    Leuk Res; 2018 May; 68():105-111. PubMed ID: 29602065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
    Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
    Molecules; 2019 May; 24(9):. PubMed ID: 31060229
    [No Abstract]   [Full Text] [Related]  

  • 9. The KDM5 family of histone demethylases as targets in oncology drug discovery.
    Rasmussen PB; Staller P
    Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
    Denis H; Van Grembergen O; Delatte B; Dedeurwaerder S; Putmans P; Calonne E; Rothé F; Sotiriou C; Fuks F; Deplus R
    Mol Biosyst; 2016 Feb; 12(2):404-13. PubMed ID: 26621457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
    Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
    Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
    Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
    Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases.
    Paroni G; Bolis M; Zanetti A; Ubezio P; Helin K; Staller P; Gerlach LO; Fratelli M; Neve RM; Terao M; Garattini E
    Oncogene; 2019 Apr; 38(15):2675-2689. PubMed ID: 30538297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.
    Hosford SR; Shee K; Wells JD; Traphagen NA; Fields JL; Hampsch RA; Kettenbach AN; Demidenko E; Miller TW
    Mol Oncol; 2019 Aug; 13(8):1778-1794. PubMed ID: 31180176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
    Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
    Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
    Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
    Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
    J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of the potential theranostic role of KDM5B/miR-29c signaling axis in paclitaxel resistant endometrial carcinoma.
    Li L; Shou H; Wang Q; Liu S
    Gene; 2019 Apr; 694():76-82. PubMed ID: 30658067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel KDM5B splice variants identified in patients with developmental disorders: Functional consequences.
    Lebrun N; Mehler-Jacob C; Poirier K; Zordan C; Lacombe D; Carion N; Billuart P; Bienvenu T
    Gene; 2018 Dec; 679():305-313. PubMed ID: 30217758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.